evo真人视讯

Brief News | Wang Ning, First-Level Researcher of the Shenzhen Science and Technology Innovation Commission, and Delegation Visit Shenzhen Cell Valley to Inspect Construction Progress

Date:02-25  Hits:  Belong to:News

图片.png

On the morning of February 24, 2023, Wang Ning, First-Level Researcher of the Innovation Development Division of the Shenzhen Science and Technology Innovation Commission, and Liao Wen, Director of the Pingshan District Science and Technology Innovation Center, along with their delegation, visited the Shenzhen Cell Valley construction site for inspection and guidance. Shenzhen Cell Valley Chairman Professor Shi Yuanyuan and Chief Scientist Professor Wang Jianxun extended a warm welcome and accompanied the delegation during the inspection.

The delegation carefully listened to reports on the construction scale, investment status, and construction progress of the Shenzhen Cell Valley facility at the Hepalink Industrial Park. Wang Ning stated that the Shenzhen Science and Technology Innovation Commission places great importance on the Shenzhen Cell Valley construction project. As a major public service platform project in Shenzhen, the Commission and relevant departments will provide service guarantees, strengthen communication and liaison with the Shenzhen Cell Valley team, promptly resolve issues encountered during project advancement, and provide further policy assistance and services. Shi Yuanyuan expressed sincere gratitude for the care shown by the municipal and district science and technology innovation leaders and committed to completing the project construction with high quality and high standards, contributing to the development of Shenzhen's cell and gene therapy industry.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software